Halozyme Therapeutics enters the week in an unusual position: the put/call ratio has surged to a near-annual high even as the Street's analyst consensus remains firmly bullish, and short sellers are quietly adding to a position that already represents more than 12% of the free float.
The sharpest signal this week is in options. Monday's put/call ratio hit 2.32 — well above its 20-day average of 0.87 and close to its 52-week peak of 2.76. The z-score of 1.6 puts Monday's reading in the top tier of defensive days over the past year. The pattern in the history is notable: the PCR has spiked above 2.0 on several discrete sessions — September 8, August 31, August 24 — while spending most days closer to 0.33. That clustering suggests episodic bursts of put-buying rather than a sustained hedging trend, possibly tied to specific events or roll dates, but Monday's print is the most recent and one of the larger spikes in the data window.
Short positioning tells a consistent, if less dramatic, story. At 12.5% of the free float, short interest is unambiguously elevated. It has crept 3.2% higher on the week and is up roughly 8% from the mid-August lows near 13.6 million shares. The borrow market is not distressed — cost to borrow is just 0.57%, even after ticking up 7% on the week, and availability at 279% means there are nearly three shares available for every one already borrowed. Shorts are not being squeezed, and new shorts can establish positions cheaply. The ORTEX short score at 67.4 — rangebound in the mid-to-upper 60s for the past two weeks — reflects a stock where bearish positioning is meaningful but not at an extreme.
The analyst community remains broadly constructive, though some of the optimism predates the stock's recent move. Leerink Partners upgraded to Outperform in early August, raising its target from $83 to $110. TD Cowen lifted its target to $105 from $96 the same day. HC Wainwright reiterated Buy with a $115 target as recently as September 2 — the highest target among the group, and now above the current $106.25 price. Wells Fargo, the one Equal-Weight holdout in the recent changes, raised its target to $95, still a discount to the current price. The consensus is buy, but with four buy-rated analysts and targets ranging from $93 to $115, the upside case is not unanimous, and the stock has already moved significantly — up roughly 8% over the past month and around 60% year-to-date per the peer note context. EPS estimates for the forward 12 months rank in the 92nd percentile for year-on-year growth, the clear fundamental anchor for bulls. The bear case centres on competitive pressure to ENHANZE as more partners find success, and management's own caution about closing new partnerships in certain programs.
The most concrete recent development is CEO Helen Torley's accelerated selling under a pre-arranged 10b5-1 plan. On September 9, 10, and 11, she exercised stock options at $18.41 per share and sold the resulting shares into the market at prices around $107–$109, with net cash proceeds of roughly $4.5 million across those three days. Net insider selling over the past 90 days totals approximately $13.7 million across 132,000 shares. Because these transactions are under a 10b5-1 plan — filed in advance with no discretion at the time of execution — they carry less signal than discretionary open-market sales. Even so, the volume and recency are worth flagging alongside the options activity. The broader institutional ownership picture shows BlackRock adding shares to bring its stake to approximately 11.7%, while State Street and Vanguard entities hold stable, passive-looking positions.
Earnings are scheduled for October 27. The last quarterly report in early August produced a single-day move of more than 23% higher, with a five-day gain of over 20% — an outsized positive reaction that drove much of the year's performance. Whether the options market is pricing residual concern about giving back those gains, or building fresh hedges ahead of the October print, is what the next few weeks of PCR readings will help clarify.
See the live data behind this article on ORTEX.
Open HALO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
